EyePoint, Inc. (EYPT)
| Market Cap | 1.22B +115.8% |
| Revenue (ttm) | 7.61M -86.4% |
| Net Income | -271.60M |
| EPS | -3.51 |
| Shares Out | 83.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 995,670 |
| Open | 13.62 |
| Previous Close | 13.73 |
| Day's Range | 13.61 - 14.88 |
| 52-Week Range | 7.94 - 19.11 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 37.00 (+153.25%) |
| Earnings Date | Aug 5, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 153.25% from the latest price.
News
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...
EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
DURAVYU, a sustained-release retinal therapy, is advancing through phase III trials for wet AMD and DME, with key data readouts expected soon. The product offers both anti-VEGF and anti-inflammatory effects, strong safety, and commercial readiness, supported by a robust financial runway.
EyePoint Transcript: Jefferies Global Healthcare Conference 2026
DURAVYU is advancing through four phase III trials for wet AMD and DME, with key readouts expected in 2024. The therapy aims for non-inferiority in visual acuity, strong safety, and meaningful reduction in treatment burden, while offering a novel mechanism and commercial advantages.
EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum
Phase III trials for DURAVYU in wet AMD and DME are progressing, with key readouts expected in August and late 2027. The drug aims for six-month dosing, offers a differentiated mechanism, and is supported by strong safety and efficacy data. Commercial launch preparations and financial runway extend into 2027.
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se...
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
EyePoint (EYPT) announced the independent data safety monitoring committee completed its third scheduled review of the company’s pivotal Phase 3 program evaluating Duravyu for wet age-related macular ...
EyePoint's late-stage eye drug trials to continue after safety panel review
EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies continue unchanged.
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously...
EyePoint reports Q1 EPS (99c), consensus (81c)
Reports Q1 revenue $696,000, consensus $352,830. “We are entering an important time for EyePoint (EYPT) and the retina community with Phase 3 topline data for DURAVYU in wet AMD expected…
EyePoint Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and operational progress, with pivotal DURAVYU phase III trials advancing in wet AMD and DME, robust safety data, and commercial readiness activities underway. Cash reserves of $223M support operations into late 2027.
EyePoint Earnings release: Q1 2026
EyePoint released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
EyePoint Quarterly report: Q1 2026
EyePoint has published its Q1 2026 quarterly earnings report on May 6, 2026.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se...
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
EyePoint Proxy statement: Proxy filing
EyePoint filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
EyePoint Proxy statement: Proxy filing
EyePoint filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
EyePoint Slides: Corporate presentation
EyePoint has posted slides in relation to its latest quarterly earnings report, which was published on April 23, 2026.
EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference
DURAVYU is advancing through four phase III trials for wet AMD and DME, with strong safety and efficacy data supporting non-inferiority to EYLEA and significant reduction in treatment burden. Top-line results for LUGANO are expected in August, and the company is well-funded through 2027.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
EyePoint price target raised to $35 from $31 at Citi
Citi raised the firm’s price target on EyePoint (EYPT) to $35 from $31 and keeps a Buy rating on the shares.
EyePoint price target raised to $30 from $23 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on EyePoint (EYPT) to $30 from $23 and keeps a Buy rating on the shares following the Q4 report. The…
EyePoint price target raised to $29 from $27 at Chardan
Chardan raised the firm’s price target on EyePoint (EYPT) to $29 from $27 and keeps a Buy rating on the shares. The firm is updating estimates after the company reported…
EyePoint Earnings Call Transcript: Q4 2025
DURAVYU advanced through pivotal Phase III trials in wet AMD and DME, supported by strong safety and efficacy data, robust cash reserves, and expanded commercial readiness. Top-line data for wet AMD is expected in mid-2026, with DME data in 2027.
EyePoint Annual report: Q4 2025
EyePoint has published its Q4 2025 annual report on March 4, 2026.
EyePoint Earnings release: Q4 2025
EyePoint released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.